Drug Development Pipeline
Hypertonic saline as an inhaled therapy is believed to increase hydration of airway surface liquid in people with CF, thereby improving mucus clearance.
A Phase 3 study conducted in Australia showed beneficial effects of hypertonic saline on pulmonary health in people with CF ages 6 years and older. A Phase 2 study of hypertonic saline in preschool children is currently underway.
The program is fully funded through the Cystic Fibrosis Foundation and facilitated by the Therapeutics Development Network Coordinating Center.
Recent Hypertonic Saline Studies
Closed to Enrollment
Completed with Results
Latest News on Hypertonic Saline
October 22, 2014
The recipients of this year's Richard C. Talamo Distinguished Clinical Achievement Award, presented at the 2014 North American Cystic Fibrosis Conference, represent a successful collaboration between researchers and clinicians to bring about a significant advance in CF care and treatment. The award is one of the highest honors given by the Cystic Fibrosis Foundation.
November 09, 2007
Early next year, researchers at the University of North Carolina (UNC) at Chapel Hill will begin enrolling infants in a clinical trial to test the effectiveness of inhaled saline as a treatment for cystic fibrosis lung disease.
January 18, 2006
An observation by surfers in Australia has led to a simple, inexpensive hypertonic saline therapy.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More